JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2016, Vol. 54 ›› Issue (2): 53-56.doi: 10.6040/j.issn.1671-7554.0.2015.743

Previous Articles     Next Articles

Clinical efficacy of bosentan in the treatment of babies with congenital heart disease complicated with pulmonary hypertension

PAN Yanyan1,2, SUN Yongchao3, ZHAO Cuifen1, KONG Qingyu1   

  1. 1. Department of Pediatrics, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Department of Pediatrics, Qilu Childrens Hospital of Shandong University, Jinan 250022, Shandong, China;
    3. Nursing Faculty, Jinan Vocational College of Nursing, Jinan 250203, Shandong, China
  • Received:2015-08-06 Online:2016-02-10 Published:2016-02-10

PDF (PC)

248

Abstract: Objectives To explore the efficacy and safety of bosentan in the treatment of infants(<3 months)with congenital heart disease complicated with pulmonary hypertension(CHD-PAH). Methods A total of 60 CHD-PAH infants treated in Qilu Hospital of Shandong University and Qilu Childrens Hospital during Jan. 2012 and Dec. 2013 were selected as the observation group and subdivided into bosentan group(n=30)and captopril group(n=30), another 30 healthy infants served as the control group. Endothelin-1(ET-1)and mean pulmonary arterial pressure(mPAP)before treatment, 4 and 8 weeks after treatment were measured with ELISA and echocardiography(UCG)in all infants. Changes of liver enzymes were measured before and after the treatment, and exercise tolerance was evaluated by observing the time changes of feeding 60 mL milk for babies in the observation group. Results ET-1 and mPAP were significantly higher in the observation group than in the control group(P<0.05). ET-1 and mPAP 4 and 8 weeks after bosentan treatment decreased significantly compared to the basement levels(P<0.01). MPAP after captopril treatment declined compared with the control group(P<0.05), while there was no statistical difference in ET-1 concentrations. ET-1 and mPAP in 山 东 大 学 学 报 (医 学 版)54卷2期 -潘艳艳,等.波生坦治疗婴儿先心病合并肺动脉高压的临床观察 \=-the bosentan treatment group decreased significantly compared with those of the captopril group 4 weeks and 8 weeks after treatment(P<0.05). There was no difference in liver enzymes before and after bosentan treatment(P>0.05). The feeding time of 60 mL milk decreased statistically 4 weeks after bosentan treatment. Conclusion Bosentan can not only effectively decrease the mean pulmonary artery pressure of infants with congenital heart disease, but also improve their exercise tolerance. Bosentan is effective and safe in the treatment of CHD-PAH infants.

Key words: Infant, Hypertension pulmonary, Bosentan, Congenital heart disease, Endothelin-1

CLC Number: 

  • R543.2
[1] Kaye AD, Stout TB, Padnos IW, et al. Left-to-right cardiac shunt: perioperative anesthetic considerations[J]. Middle East J Anaesthesiol, 2012, 21(6): 793-806.
[2] Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension[J]. Pharmacol Res, 2011, 63(6): 504-511.
[3] 张伟艳, 莫绪明. 波生坦治疗先天性心脏病合并肺动脉高压的研究进展[J]. 心肺血管病杂志, 2012, 31(3): 351-352.
[4] Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension[J]. Am J Respir Crit Care Med, 2013, 187(6): 572-575.
[5] Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology[J]. J Am Coll Cardiol, 2013, 62(25 Suppl): 22-33.
[6] Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling[J]. J Am Coll Cardiol, 2009, 54(1 Suppl): 10-19.
[7] Gabbay E, Fraser J, McNeil K. Review of bosentan in the management of pulmonary arterial hypertension[J]. Vasc Health Risk Manag, 2007, 3(6): 887-900.
[8] Stow LR, Jacobs ME, Wingo CS, et al. Endothelin-1 gene regulation[J]. FASEB J, 2011, 25(1): 16-28.
[9] Lee YH, Song GG. Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension[J]. Korean J Intern Med, 2013, 28(6): 701-707.
[10] Hall SM, Davie N, Klein N, et al. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment[J]. Eur Respir J, 2011, 38(4): 851-860.
[11] Ivy DD, Rosenzweig EB, Lemarié JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings[J]. Am J Cardiol, 2010, 106(9): 1332-1338.
[12 ] Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children[J]. Eur Respir J, 2011, 38(1): 70-77.
[13] Vis JC, Duffels MG, Mulder P, et al. Prolonged beneficial effect of bosentan treatment and 4-year survival rates in adult patients with pulmonary arterial hypertension associated with congenital heart disease[J]. Int J Caldiol, 2013, 164(1): 64-69.
[14] Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension[J]. Turk Kardiyol Dern Ars, 2014, 42(Suppl 1): 55-66.
[15] 李爱杰, 顾虹, 张陈, 等. 波生坦对儿童先天性心脏病相关肺动脉高压的治疗作用[J]. 中国医药, 2012, 7(4): 414- 416. LI Aijie, GU Hong, ZHANG Dong, et al. Outcome of bosentan treatment in children with pulmonary arterial hypertension associated with congenital heart disease[J]. China Medicine, 2012, 7(4): 414- 416.
[16] 中华医学会儿科分会心血管学组. 儿童肺高血压诊断与治疗专家共识[J]. 中华医学杂志, 2015, 53(1): 6-11.
[17] Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study[J]. Br J Clin Pharmaeol, 2009, 68(6): 948-955.
[18] Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study[J]. Heart, 2010, 96(17): 1401-1406.
[19 ] DAlto M, Romeo E, Argiento P, et al. Pulmonary vasoreactivity predicts long-term outcome in patients with Eisenmenger syndrome receiving bosentan therapy[J]. Heart, 2010, 96(18): 1475-1479.
[20] Berger RM, Beghetti M, Galie N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmengers syndrome: a subgroup analysis[J]. Int J Cardiol, 2010, 144(3): 373-378.
[21] 薛强, 鲁一兵, 张伟华, 等. 波生坦联合西地那非治疗先心病合并重度肺动脉高压的临床研究[J]. 昆明医科大学学报, 2014, 8(3): 54-57. XUE Qiang, LU Yibing, ZHANG Weihua, et al. Clinical analysis of bosentan and sildenafil in treatment of severe pulmonary anery hypertension with congenital heart disease[J]. Journal of Kunming Medical University, 2014, 8(3): 54-57.
[22] Rose ML, Strange G, King I, et al. Congenital heart disease-associated pulmonary arterial hypertension: preliminary results form a novel registry[J]. Intern Med J, 2012, 42(8): 874-879.
[1] LI Yuanyuan, WANG Ximing, WANG Long, JI Congshan, DUAN Yanhua,CHENG Zhaoping, LIU Yanping, CHEN Jing. Application of flash spiral acquisition by dual-source CT in children with cardiovascular airway constriction [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 59-64.
[2] QIU Jie, ZANG Lijiao, ZHUANG Genmiao, AN Li. Correlation between multiorgan damage and perinatal asphyxia occurred at different gestational ages [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(9): 64-68.
[3] WU Yiliang, ZHANG Linfeng, LI Yuan, LIU Xiaowen, XU Guangqi, GAO Feng, LÜ Renrong, HUO Ran. Ultra-high-frequency ultrasound vs high-frequency ultrasound in assessing superficial infantile hemangioma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(12): 72-76.
[4] LIU Huimin, LIU Deng, LI Xiaoyu, ZOU Shufeng, JIANG Limin, LI Yuhuan. Effect of Lobelia alkaloids on endothelin-1 signal pathway in a rat model of pulmonary arterial hypertension [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(8): 1-4.
[5] FU Qingyuan, DAI Guiqiang, ZHANG Song, AN Hongchun, LIANG Shimin. Effect of panax quinquefolium saponin from stems and leaves on endothelin-1, vascular endothelial growth factor and infarct area in rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 30-33.
[6] CI Chun-yan, LI Wen, LU Xian-mei . Analysis of amplitude integrated electroencephalography
characteristics in preterm infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(9): 109-112.
[7] LONG Xin-xin, WANG Xue-yu. Clinical effect and follow-up analysis of lowdose adrenocorticotropic
hormone for infantile spasms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2012, 50(5): 88-91.
[8] YANG Xueyong1, ZHOU Gengxu1, LI Qiuping2, FU Song1, LIU Yuhang1, WANG Hui1, ZHAO Xin2, FENG Zhichun3 . Bedside surgical ligation of patent ductus arteriosus in  low body weight premature infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(8): 133-135.
[9] ZHAO Bao-ming1， LI Feng-liang2， SONG Xi-ming1. Influence of advanced glycation end products on prostacyclin and endothelin-1 secretion from human vascular endothelial cells [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2011, 49(11): 5-7.
[10] LV Jianli1， YI Yingchun1， HAN Bo1， ZHANG Jianjun1， ZHUANG Jianxin1， SUN Yiping1， ZHAO Lijian1， WANG Ximing2， DUAN Yanhua2， WANG Anbiao3， LI. Clinical value of dualsource spiral CT in the diagnosis of congenital heart disease in children [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(7): 77-82.
[11] YU Haili, WANG Xueyu, XI Jiashui, SUN Wenxiu. A comparative study on the efficacy and adverse reactions of two different dosages of  adrenocorticotropic hormone therapy for infantile spasms [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(2): 100-104.
[12] . Audiological features of auditory steadystate response and auditory brain stem response in large vestibular aqueduct syndrome [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(8): 89-92.
[13] ZHANG Ai-Hua, YANG Da-Kuan. Continuous ultrafiltration during cardiopulmonary bypass in infants [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(5): 99-101.
[14] FANG Ying-li,LIU Ai-ting,ZHOU Wen. Relationship between time and concentration of Lacto-tinidazole after drug combination [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(8): 815-818.
[15] ZHANG Meng-yuan,XU Yan-bing,YAN Qing-fu. CABG with off-pump technique or cardiopulmonary bypass for serum Endothelin-1 and left ventricular function [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(6): 594-596.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd